國家衛生研究院 NHRI:Item 3990099045/4334

NHRI > Institute of Biomedical Engineering and Nanomedicine > Feng-Huei Lin > Conference Papers/Meeting Abstract > Item 3990099045/4334

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/4334

Title:	Development of EGFR-targeting nanomedicine for effectively and noninvasively treats lung cancer patients by aerosol delivery
Other Titles:	World Congress on Medical Physics and Biomedical Engineering: Micro- and Nanosystems in Medicine, Active Implants, Biosensors
Authors:	Tseng, CL;Wu, YH;Yu, SW;Yang, KC;Lin, FH
Contributors:	Division of Medical Engineering Research
Abstract:	Lung cancer is a harmful form of cancer. The long-term survival rate of lung cancer patients treated by conventional modalities remains far from satisfactory. Encapsulated anticancer drugs in nanocarriers, can protect not only the integrity of drugs during transport but also the normal tissues from the toxicity. To develop an effective drug delivery system for lung cancer therapy, gelatin nanoparticles (GPs) were modified with NeutrAvidin <sup>FITC</sup>-biotinylated epidermal growth factor (bEGF) to form EGF receptor (EGFR)-seeking nanoparticles (GP-Av-bEGF). Cisplatin, a key drug used in the chemotherapy with sever side effect, was incorporated in the nanocarriers for active targeting to reduce toxicity. Furthermore, these nanocarriers were given to mice via inhalation of aerosol droplets which were generated by a nebulizer and delivered to mice model of lung cancer via aerosol. To summarize, the in vivo targeting ability of GP-Av-bEGF was examined by fluorescence images obtained from live mice showed that these nanoparticles could target the cancerous lungs in a more specific manner by aerosol delivery. And gelatin nanoparticles loaded with cisplatin and decorated with EGF tumor-specific ligand (GP-PtbEGF) were also successfully developed. Their in vitro and in vivo targeting ability and anticancer effect were confirmed. This treatment showed that GP-Pt-bEGF had stronger antitumor activity and was less toxic compared with other cisplatin formulas. Furthermore, these formulations were given to mice with lung cancer via aerosol delivery and showed that inhaled GP-Pt-bEGF could target EGFR-overexpressing cells to achieve high cisplatin dosage in cancerous lungs. The aerosol delivery of nanocarriers was demonstrated here. Simple aerosol delivery of targeted drug carriers may prove useful for the clinical treatment of lung cancer patients to eliminate patient complaints associated with the frequent intravenous injection.
Date:	2009-09
Relation:	IFMBE Proceedings. 2009 Sep;25(8):347-350.
Link to:	http://dx.doi.org/10.1007/978-3-642-03887-7
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000291667000100
Cited Times(Scopus):	http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=77949903150
Appears in Collections:	[Feng-Huei Lin] Conference Papers/Meeting Abstract

Files in This Item:

File	Description	Size	Format
SCP77949903150.pdf		745Kb	Adobe PDF	547	View/Open

Loading...